Skip to Main Content

About Us
Vision
Science
News
Careers
Contact

Scorpion, seeking to develop ‘precision medicine’ drugs for cancer, debuts with $108m in funding

Boston Globe | October 26, 2020

Gary Glick is chief executive of Scorpion Therapeutics. Courtesy of Scorpion Therapeutics. Scorpion Therapeutics is the latest biotech to debut in Boston, with $108 million in venture capital and a roster of local industry veterans. The startup is focused on targeted oncology, or “precision medicine” for cancer, and will be headed by Gary Glick, who comes most recently from Boston-based IFM Therapeutics. There, he brought three immunotherapy drugs to clinical trials in three years, closing big pharmaceutical deals for their rights with Bristol Myers Squibb and Novartis.

Read the article

Privacy Policy
Terms of Use

© 2021 All Right Reserved.

Linkedin
Twitter

About Us
Vision
Science
News
Careers
Contact